← Leaderboards
Danny Bluestein
State University New York Stony Brook
$18,648,248
Attributed
$18,648,248
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2007–22$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$18,648,248 · 7
By mechanism
U01$14,326,428 · 3
R42$1,989,089 · 1
R01$1,686,334 · 1
R21$421,397 · 1
R41$225,000 · 1
Top collaborators
No co-investigators on record.
Most similar at State University New York Stony Brook
Same institution · by research overlap
- Patrick Hearing$15,345,877
- Eckard Wimmer$15,650,559
- Arthur P Grollman$9,461,519
- James B Bliska$15,447,088
- Erich R. Mackow$15,406,345
Others in their field
Top investigators on “Stress”
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S Hochman · New York University School Of Medicine$109,572,916
- James E. Gern · University Of Wisconsin-Madison$100,351,848
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Robert O Wright · Brigham And Women'S Hospital$71,259,719
- Leonardo Trasande · New York University School Of Medicine$59,472,515
Research focus
StressInnovationBlood PlateletsDevicesSimulationMethodologyIn VitroTechnologyHemodynamicsDesignSavingsLiquid SubstanceMeasurementCardiovascular SystemPropertyLeadPrototypePerformanceQuantumLifeMechanicsTherapeutic EmbolizationBaseTissues
Grant awards (25)
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes$763,857
U01 · FY2022 · EB · contact PI
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement$594,265
R42 · FY2022 · HL · contact PI
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes$748,628
U01 · FY2021 · EB · contact PI
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement$675,649
R42 · FY2021 · HL · contact PI
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes$764,216
U01 · FY2020 · EB · contact PI
Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis$729,811
U01 · FY2020 · HL · contact PI
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement$719,175
R42 · FY2020 · HL · contact PI
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes$767,246
U01 · FY2019 · EB · contact PI
Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis$729,811
U01 · FY2019 · HL · contact PI
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes$781,199
U01 · FY2018 · EB · contact PI
Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis$729,811
U01 · FY2018 · HL · contact PI
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement$110,257
R41 · FY2018 · HL · contact PI
Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis$718,221
U01 · FY2017 · HL · contact PI
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement$114,743
R41 · FY2017 · HL · contact PI
Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis$689,406
U01 · FY2016 · HL · contact PI
Optimizing Cardiovascular Device Thromboresistance for Eliminating Anticoagulants$1,308,032
U01 · FY2014 · EB · contact PI
Optimizing Cardiovascular Device Thromboresistance for Eliminating Anticoagulants$1,295,374
U01 · FY2013 · EB · contact PI
Optimizing Cardiovascular Device Thromboresistance for Eliminating Anticoagulants$1,399,855
U01 · FY2012 · EB · contact PI
Multiscale modeling of blood flow and clotting in cardiovascular devices$230,726
R21 · FY2012 · HL · contact PI
Optimizing Cardiovascular Device Thromboresistance for Eliminating Anticoagulants$1,414,610
U01 · FY2011 · EB · contact PI
Multiscale modeling of blood flow and clotting in cardiovascular devices$190,671
R21 · FY2011 · HL · contact PI
Optimizing Cardiovascular Device Thromboresistance for Eliminating Anticoagulants$1,486,351
U01 · FY2010 · EB · contact PI
Optimizing Cardiovascular Devices Thrombogenicity for Eliminating Anticoagulation$577,575
R01 · FY2009 · EB · contact PI
Optimizing Cardiovascular Devices Thrombogenicity for Eliminating Anticoagulation$552,070
R01 · FY2008 · EB · contact PI
Optimizing Cardiovascular Devices Thrombogenicity for Eliminating Anticoagulation$556,689
R01 · FY2007 · EB · contact PI